Europe Opioid Induced Constipation (OIC) Drug Market Forecast 2017-2025

Publisher Name :
Date: 24-Sep-2017
No. of pages: 62

Key Findings

The Europe opioid-induced constipation drug market is expected to grow at a CAGR of 7.51% during the forecast period of 2017-2025. The market value is predicted to increase from $1497million in 2016 and reach up to $2877 million by the end of 2025.

Market Insights

The Europe opioid constipation drug market is mainly driven by the increasing opioids prescription in the region. The market can be segmented into two criteria. First is the market by drug type that includes drugs such as naloxegol, methyl naltrexone bromide, lubiprostone, others. Of these, lubiprostone is currently the most popular drug type in the region. The second market segmentation criteria is on the basis of the type of prescription that includes over the counter drugs and branded or generic prescribed drugs. The over the counter drugs are more popular as compared to the prescribed ones due to their ease of availability.

Competitive Insights

Some of the noted companies in the market include Pfizer, Daiichi Sankyo Co Ltd, Theravance Biopharma Inc, Progenics Pharmaceuticals Inc, Allergan Plc, Purdue Pharma L.P., Valeant Pharmaceuticals International, Cosmo Pharmaceuticals Sa,C.B. Fleet Company, and Nektar Therapeutics.

Europe Opioid Induced Constipation (OIC) Drug Market Forecast 2017-2025

Table of Contents

1. Research Scope
1.1. Study Goals
1.2. Scope of The Market Study
1.3. Who Will Find This Report Useful?
1.4. Study and Forecasting Years
2. Research Methodology
2.1. Sources of Data
2.1.1. Secondary Data
2.1.2. Primary Data
2.2. Top Down Approach
2.3. Bottom-Up Approach
2.4. Data Triangulation
3. Executive Summary
3.1. Market Summary
4. Market Overview
4.1. Market Definition
4.2. Key Market Insights
4.3. Attractive Investment Scenario
4.4. Positioning of Key Oic Drugs Manufacturers In The Market
4.5. Market Drivers
4.5.1. Rising Use of Opioid
4.5.2. Increasing Geriatric Population
4.5.3. Increasing Opioids Prescription In Europe
4.5.4. Easy Availability of Improved and Effective Oic Drugs
4.6. Restraints
4.6.1. Research On Pain and Next Generation Analgesics
4.6.2. Side Effects of Oic Drugs
4.6.3. Unawareness and Ignorance Among Patients
4.7. Opportunity
4.7.1. Increasing Use of Opioids
4.8. Challenges
4.8.1. Large Number of Considerations While Using Opioids
5. Europe Oic Drug Market By Drug Type 2017-2025 ($ Million)
5.1. Overview
5.1.1. Methyl Naltrexone Bromide
5.1.2. Lubiprostone
5.1.3. Naloxegol
5.2. Pipeline Drug Analysis: Phase 3: Naldemedine (Year of Launch To 2022 $ Million)
5.3. Pipeline Drug Analysis: Phase 2: Alvimopan, Dolcanatide (Qualitative Information)
5.4. Pipeline Drug Analysis: Phase 3: Elobixibat (Year of Launch To 2022 $ Million)
6. Europe Oic Drugs Market By Prescription Type 2017-2025 ($ Million)
6.1. Prescribed Drugs
6.1.1. Branded
6.1.2. Generic
6.2. Over The Counter Drugs
7. Key Analytics
7.1. Porters Five Force Model
7.1.1. Intensity of Competitive Rivalry
7.1.2. Bargaining Power of Suppliers
7.1.3. Bargaining Power of Buyers
7.1.4. Threat of Substitute Products
7.1.5. Threat of New Entrants
7.2. Vendor Landscape
7.3. Opportunity Matrix
8. Europe Oic Drugs Market By Countries 2017-2025 ($ Million)
8.1. Uk
8.2. Germany
8.3. Rest of The Europe
9. Company Profile
9.1. Ironwood Pharmaceuticals Inc
9.1.1. Overview
9.1.2. Product Portfolio
9.1.3. Strategic Moves
9.1.4. Scot Analysis
9.2. Daiichi Sankyo Co Ltd
9.2.1. Overview
9.2.2. Product Portfolio
9.2.3. Strategic Moves
9.2.4. Scot Analysis
9.3. Pfizer
9.3.1. Overview
9.3.2. Product Portfolio
9.3.3. Strategic Moves
9.3.4. Scot Analysis
9.4. Progenics Pharmaceuticals Inc
9.4.1. Overview
9.4.2. Strategic Moves
9.4.3. Scot Analysis
9.5. Shionogi & Co., Ltd.
9.5.1. Overview
9.5.2. Product Portfolio
9.5.3. Strategic Moves
9.5.4. Scot Analysis
9.6. Allergan Plc
9.6.1. Overview
9.6.2. Product Portfolio
9.6.3. Strategic Moves
9.6.4. Scot Analysis
9.7. Nektar Therapeutics
9.7.1. Overview
9.7.2. Product Portfolio
9.7.3. Strategic Moves
9.7.4. Scot Analysis
9.8. Purdue Pharma L.P.
9.8.1. Overview
9.8.2. Product Portfolio
9.8.3. Strategic Moves
9.8.4. Scot Analysis
9.9. S.L.A. Pharma Ag
9.9.1. Overview
9.9.2. Product Portfolio
9.9.3. Scot Analysis
9.10. Mundipharma International Limited
9.10.1. Overview
9.10.2. Product Portfolio
9.10.3. Strategic Moves
9.10.4. Scot Analysis
9.11. Ono Pharmaceutical Co., Ltd.
9.11.1. Overview
9.11.2. Product Portfolio
9.11.3. Strategic Moves
9.11.4. Scot Analysis
9.12. Takeda Pharmaceutical Company Limited
9.12.1. Overview
9.12.2. Product Portfolio
9.12.3. Strategic Moves
9.12.4. Scot Analysis
9.13. Theravance Biopharma Inc
9.13.1. Overview
9.13.2. Product Portfolio
9.13.3. Strategic Moves
9.13.4. Scot Analysis
9.14. Valeant Pharmaceuticals International
9.14.1. Overview
9.14.2. Product Portfolio
9.14.3. Strategic Moves
9.14.4. Scot Analysis
9.15. Cosmo Pharmaceuticals Sa
9.15.1. Overview
9.15.2. Product Portfolio
9.15.3. Strategic Moves
9.15.4. Scot Analysis
9.16. Daewoong Pharmaceutical Co., Ltd.
9.16.1. Overview
9.16.2. Product Portfolio
9.16.3. Strategic Moves
9.16.4. Scot Analysis
9.17. C.B. Fleet Company, Inc.
9.17.1. Overview
9.17.2. Product Portfolio
9.17.3. Strategic Moves
9.17.4. Scot Analysis
9.18. Sucampo Pharmaceuticals
9.18.1. Overview
9.18.2. Product Portfolio
9.18.3. Strategic Moves
9.18.4. Scot Analysis

List of Tables
Table 1 Europe Oic Drug Market By Countries 2017-2025 ($ Million)
Table 2 Pharmacological Approaches To Treat Opioid Induced Constipation
Table 3 Laxatives Used For Opioid Induced Constipation
Table 4 Side Effects of Using Laxatives
Table 5 Patients Unfit For Intake of Opioids
Table 6 Europe Oic Drug Market By Drug Type, 2017-2025 ($ Million)
Table 7 Product Profile (Methyl Naltrexone Bromide)
Table 8 Product Profile (Lubiprostone)
Table 9 Product Profile (Naloxegol)
Table 10 Pipeline Product Profile (Naldemedine)
Table 11 Pipeline Product Profile (Alvimopan, Dolcanatide)
Table 12 Pipeline Product Profile (Elobixibat)
Table 13 Europe Oic Drug Market By Prescription Type 2017-2025 ($ Million)
Table 14 Product Profile (Lubiprostone)
Table 15 Europe Prescribed Oic Drugs Market 2017-2025($ Million)
Table 16 Product Profile (Methyl Naltrexone Bromide)
Table 17 Product Profile (Metamucil)
Table 18 Product Profile (Bisacodyl)
Table 19 Europe Oic Drug Market By Countries 2017-2025 ($ Million)

List of Figures
Figure 1 Europe Oic Drugs Market 2017-2025 ($ Million)
Figure 2 Europe Oic Drug Market By Drug Type 2016 and 2025 (%)
Figure 3 Europe Oic Drug Market By Prescription Type 2016 (%)
Figure 4 Increasing Number of Opioid Prescription ($ Million)
Figure 5 Reasons For The Growth of Opioid Market.
Figure 6 Common Side Effects of Movantik
Figure 7 Major Usage of Opioids
Figure 8 Considerations Taken While The Opioid Usage
Figure 9 Europe Methyl Naltrexone Bromide Oic Drug Market 2017-2025 ($ Million)
Figure 10 Europe Lubiprostone Oic Drug Market 2017-2025 ($Million)
Figure 11 Europe Naloxegol Oic Drug Market 2017-2025 ($ Million)
Figure 12 Europe Prescribed Oic Drug Market 2017-2025 ($ Million)
Figure 13 Europe Prescribed Branded Oic Drug Market 2017-2025 ($ Million)
Figure 14 Europe Prescribed Generic Oic Drug Market 2017-2025 ($ Million)
Figure 15 Europe Over The Counter Oic Drug Market 2017-2025 ($ Million)
Figure 16 Europe Oic Drug Market 2017-2025 ($ Million)
Figure 17 Uk Oic Drug Market 2017-2025 ($ Million)
Figure 18 Germany Oic Drug Market 2017-2025 ($ Million)
Figure 19 Rest of Europe Oic Drug Market 2017-2025($ Million)
  • Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2018
    Published: 17-Jul-2018        Price: US 2000 Onwards        Pages: 601
    Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2018, provides an overview of the Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline landscape. Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver. NASH can get worse and cause scarrin......
  • Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2018
    Published: 17-Jul-2018        Price: US 2000 Onwards        Pages: 243
    Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2018, provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline landscape. Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease. Nonalcoholic fatty li......
  • Global Esomeprazole Market Research Report 2018
    Published: 13-Jul-2018        Price: US 2900 Onwards        Pages: 93
    This report studies the global Esomeprazole market status and forecast, categorizes the global Esomeprazole market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa. The global Esomeprazole market is valued at million US$ in 2017 and will reach million US$ by the end of 2025, growing at a CAGR of during 2018-2025. The major man......
  • 2018-2023 Global Gastrointestinal Consumption Market Report
    Published: 12-Jul-2018        Price: US 4660 Onwards        Pages: 164
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Gastrointestinal market for 2018-2023. Gastrointestinal (GI) disorders include functional bowel diseases such as irritable bowel syndrome (IBS) and inflammatory bowel diseases such as Crohn's disease (CD) and colitis. Some gastrointestinal drug can control or moderate the symptoms of gastrointestinal disorders. The global average gross margin of Gast......
  • 2018 Top 5 Gastrointestinal Players in North America, Europe, Asia-Pacific, South America, Middle East and Africa
    Published: 12-Jul-2018        Price: US 4960 Onwards        Pages: 145
    Gastrointestinal (GI) disorders include functional bowel diseases such as irritable bowel syndrome (IBS) and inflammatory bowel diseases such as Crohn's disease (CD) and colitis. Some gastrointestinal drug can control or moderate the symptoms of gastrointestinal disorders. The global average gross margin of Gastrointestinal is in a slight decreasing trend, and the gross margin is 63% in 2015. Europe region is the largest supplier of Gastrointestinal, with a production revenue marke......
  • Hepatic Encephalopathy - Pipeline Review, H2 2018
    Published: 10-Jul-2018        Price: US 2000 Onwards        Pages: 72
    Hepatic Encephalopathy - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatic Encephalopathy - Pipeline Review, H2 2018, provides an overview of the Hepatic Encephalopathy (Gastrointestinal) pipeline landscape. Hepatic encephalopathy is a worsening of brain function that occurs when the liver is no longer able to remove toxic substances in the blood. Symptoms include disorientation, dro......
  • Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2018
    Published: 10-Jul-2018        Price: US 2000 Onwards        Pages: 35
    Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2018, provides an overview of the Functional (Non Ulcer) Dyspepsia (Gastrointestinal) pipeline landscape. Non-ulcer dyspepsia is a term used to describe signs and symptoms of indigestion that have no obvious cause. Non-ulcer dyspepsia is also called func......
  • Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline Review, H2 2018
    Published: 10-Jul-2018        Price: US 2000 Onwards        Pages: 91
    Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atypical Hemolytic Uremic Syndrome - Pipeline Review, H2 2018, provides an overview of the Atypical Hemolytic Uremic Syndrome (Gastrointestinal) pipeline landscape. Atypical hemolytic uremic syndrome is a disease that primarily affects kidney function. T......
  • Colitis - Pipeline Review, H2 2018
    Published: 10-Jul-2018        Price: US 2000 Onwards        Pages: 108
    Colitis - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colitis - Pipeline Review, H2 2018, provides an overview of the Colitis (Gastrointestinal) pipeline landscape. Colitis is swelling (inflammation) of the large intestine (colon). Colitis can have many different causes, including infections, including those caused by a virus, parasite, and food poisoning due to bacteria, inflammatory ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs